Cellular Map of Healthy Pancreas Reveals Origins of Aggressive Tumors, Challenging One-Size-Fits-All Treatment
Key Insights
VUB researchers mapped the healthy human pancreas at cellular resolution, revealing that the large drainage ducts possess a layered structure rather than a simple single-cell composition.
A rare cell group was discovered in healthy tissue that already bears strong similarities to the most aggressive pancreatic tumor cells, opening avenues for early detection.
In adenosquamous carcinoma (search) (ASCP), the rare but aggressive variant, the specific cell types and spatial architecture of the healthy duct are almost perfectly preserved, unlike in classical PDAC where organization is obliterated.
Scientists at the Free University of Brussels (VUB) have produced a detailed cellular map of the healthy human pancreas that fundamentally reshapes understanding of how pancreatic cancers arise and how they should be treated. Published in the journal Gut, the research reveals that rare cells residing in the organ's drainage ducts already display characteristics previously thought exclusive to aggressive tumor cells—a discovery with profound implications for early detection and personalized therapy.
The work was led by Professor Dr Ilse Rooman at the VUB's Translational Oncology Research Centre, with PhD researcher Jan-Lars Van den Bossche as the study's first author.
A new anatomy of the pancreatic duct
Traditionally, the tissue lining the pancreatic drainage ducts—where most pancreatic tumors originate—was considered a simple, uniform structure composed of a single basic cell type. The VUB team overturned this assumption using advanced single-cell and spatial technologies to map the healthy human pancreas in unprecedented detail.
The researchers discovered that the large drainage ducts can exhibit a layered, or stratified, architecture. Within this organization, they identified a rare cell population that possesses specific molecular properties previously attributed exclusively to aggressive cancer cells.
"Understanding cancer starts with knowing about the healthy organ," said Professor Rooman. "Now that we know that these cells are already naturally present, we can start investigating whether they play a role in the development of the tumour. This may offer opportunities for early detection."
Divergent fates: PDAC versus ASCP
When the team compared their healthy-tissue atlas with samples from pancreatic cancer patients, striking differences emerged between the two major histological subtypes.
In pancreatic ductal adenocarcinoma (search) (PDAC), the most common variant, the original cellular organization was found to be completely obliterated. The tumor appears to erase the native architecture of the duct.
The picture was markedly different for adenosquamous carcinoma (search) (ASCP), a rarer but extremely aggressive form of the disease. In ASCP tumors, the specific cell types and their exact spatial structure—faithfully mirroring the healthy duct—were almost perfectly preserved.
Implications for treatment
The findings carry immediate clinical relevance. Currently, patients diagnosed with the rarer ASCP variant receive the same treatment regimen as those with classical PDAC. The VUB researchers argue this one-size-fits-all approach is no longer tenable.
Because ASCP tumors retain the cellular architecture of the healthy duct, they may be vulnerable to therapeutic strategies that specifically target those preserved structures. The exposed cell populations offer a new perspective for developing subtype-specific interventions.
The study, titled "Luminal-basal stratification of the native human pancreatic duct is differentially represented in pancreatic cancers," was published online first on June 4, 2026, in Gut (doi: 10.1136/gutjnl-2025-337970).